FRA:HPR (Ireland)
Â
Business Description
Horizon Therapeutics PLC
NAICS : 325412
SIC : 2834
Description
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | 2.42 | |||||
| Interest Coverage | 8.4 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.86 | |||||
| Beneish M-Score | -2.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.5 | |||||
| 3-Year EBITDA Growth Rate | 30 | |||||
| 3-Year FCF Growth Rate | 53.3 | |||||
| 3-Year Book Growth Rate | 42.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.06 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.34 | |||||
| 9-Day RSI | 35.45 | |||||
| 14-Day RSI | 46.16 | |||||
| 6-1 Month Momentum % | 28.66 | |||||
| 12-1 Month Momentum % | 33.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.96 | |||||
| Quick Ratio | 3.74 | |||||
| Cash Ratio | 2.5 | |||||
| Days Inventory | 85.9 | |||||
| Days Sales Outstanding | 67.3 | |||||
| Days Payable | 15.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.4 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.12 | |||||
| Operating Margin % | 19.8 | |||||
| Net Margin % | 15.51 | |||||
| ROE % | 12 | |||||
| ROA % | 6.54 | |||||
| ROIC % | 11.42 | |||||
| ROC (Joel Greenblatt) % | 89.75 | |||||
| ROCE % | 8.45 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 45.1 | |||||
| Forward PE Ratio | 21.15 | |||||
| PE Ratio without NRI | 45.1 | |||||
| Price-to-Owner-Earnings | 26.26 | |||||
| PS Ratio | 7.02 | |||||
| PB Ratio | 5 | |||||
| Price-to-Tangible-Book | 55.38 | |||||
| Price-to-Free-Cash-Flow | 20.46 | |||||
| Price-to-Operating-Cash-Flow | 18.97 | |||||
| EV-to-EBIT | 38.08 | |||||
| EV-to-Forward-EBIT | 22.47 | |||||
| EV-to-EBITDA | 24.12 | |||||
| EV-to-Forward-EBITDA | 13.58 | |||||
| EV-to-Revenue | 6.9 | |||||
| EV-to-Forward-Revenue | 6.56 | |||||
| EV-to-FCF | 20.1 | |||||
| Price-to-Projected-FCF | 2.25 | |||||
| Price-to-Median-PS-Value | 1.55 | |||||
| Price-to-Graham-Number | 10.52 | |||||
| Earnings Yield (Greenblatt) % | 2.63 |
